Vision
Vision loss from glaucoma and diabetic retinopathy remains a major global health concern. Our research explores how improving retinal blood flow and nutrient delivery may protect nerve cells responsible for sight. This work aims to complement existing pressure-lowering treatments by addressing metabolic and circulatory challenges that contribute to disease progression.
-
Traditional glaucoma treatments focus on lowering intraocular pressure (fluid pressure inside the eye), yet many patients continue to lose vision even with normal readings.
BioShift investigates how improving the ocular blood flow and nutrient delivery could protect the retinal ganglion cells that enable sight.
-
BioShift is evaluating Tricaprin supplementation for patients with non-proliferative diabetic retinopathy (NPDR).
The program tracks changes in retinal health using fundus photography, fluorescein angiography, and visual acuity testing to assess whether metabolic support can slow disease progression.
Contributions to our general fund enables ongoing laboratory and imaging studies that deepen understanding of retinal oxygenation, nutrient transport, and neuroprotection. Your help maintains the resources and equipment necessary to advance this work towards meaningful clinical insights.
Donate
